AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03737708 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab
Description: Administered by intravenous injection
Study NCT03737708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Administered by intravenous injection
Study NCT03737708 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: abatacept
Description: Administered by intravenous injection
Study NCT03651063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computer group
Description: reach to grasp games with a computer screen
Study NCT02709642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit Contract
Description: A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of earning it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer.
Study NCT04000659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Episealer Knee System
Description: The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
Study NCT04000659 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Microfracture
Description: Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
Study NCT02831829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water-based exercise training
Description: Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
Study NCT02831829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: land-based exercise training
Description: Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
Study NCT03335930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a 12-week moderate-intensity exercise training
Description: a 12-week, aerobic, moderate-intensity exercise training
Study NCT03335930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a 12-week moderate-intensity exercise training
Description: a 12-week, aerobic, moderate-intensity exercise training
Study NCT03423875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PrEDICT game score
Description: PrEDICT game score will be shared with the emergency physicians and health care professionals
Study NCT00347100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Throughout study period
Study NCT00347100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Study NCT00347100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyclazide
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Study NCT00347100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimiperide
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Study NCT00347100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Study NCT00347100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Study NCT00347100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Study NCT02055703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2609
Study NCT02055703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Study NCT02055703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Study NCT02055703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Study NCT02055703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Study NCT03117517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (1000 mg)
Study NCT03117517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, Pioglitazone
Description: Metformin (1000 mg) Pioglitazone (30 mg)
Study NCT02110446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS-1
Description: The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
Study NCT02110446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Study NCT04449133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD128
Description: Oral administration of two capsules before sleep for 7 days.
Study NCT03737708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Administered by intravenous injection
Study NCT00766896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (platelet sensitive versus platelet hyperreactivity)
Description: The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release).
Study NCT00814515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NOVA22007 (Ciclosporin 0.1%)
Description: Ciclosporin 0.1% Ophthalmic Emulsions
Study NCT00814515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NOVA22007
Description: Vehicle
Study NCT00791115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole-mount sectioning of the prostate
Description: A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
Study NCT02569450 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surgical outcomes monitoring using Shewhart control chart
Description: * Assistance by a local surgeon responsible for the implementation of intervention within his/her department~* Quarterly team meeting to interpret variations in observed outcomes on the control charts~* Restitution of surgical outcomes based on wall posters in operating room~* Training sessions provided to local surgeon for appropriate control chart utilization
Study NCT00874653 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Women using Mirena for intrauterine treatment of menorrhagia
Study NCT04358341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/m2 ivdrip every 14 days
Study NCT04358341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXOrubicin Liposome Injection
Description: 25 mg/m2 ivdrip every 14 days
Study NCT04358341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5fluorouracil
Description: 400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
Study NCT04853901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days
Study NCT04853901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care_1
Description: Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days
Study NCT04853901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care_2
Description: Methylprednisolone 1-2mg/kg for 5-7 days
Study NCT02083003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyamine low-diet
Study NCT02083003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liberal alimentation
Study NCT01486602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV
Study NCT01486602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV
Study NCT01486602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Defined per the protocol
Study NCT00917267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: 2.0mg subcutaneous injection, once a week
Study NCT00917267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide twice daily
Description: 5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
Study NCT00404534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin, Clarythromycin, Omeprazole for ten days
Description: Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
Study NCT00404534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin, Clarythromycin, Omeprazole for ten days
Description: Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
Study NCT01532180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aura6000 System
Description: The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
Study NCT03218761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NET mRNA level
Description: quantification of mRNA to the Norepinephrine Transporter (NET)
Study NCT03218761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma catechols
Description: plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
Study NCT03218761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Catechols
Description: urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
Study NCT06350461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of hypertonic saline (HS)
Description: Discontinuation of current hypertonic saline (HS) therapy during 6-week study period.
Study NCT06350461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of hypertonic saline (HS)
Description: Continuation of current hypertonic saline (HS) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
Study NCT00558662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coban 2
Description: Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
Study NCT00558662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SSB
Description: Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
Study NCT03128437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 \[lower bound\] or 0.80 \[upper bound\]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
Study NCT00665990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
Study NCT00665990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
Study NCT00665990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
Study NCT02936037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003 100mg capsule
Study NCT02936037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: an inactive substance
Study NCT02732093 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: stellate block
Study NCT02732093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stellate block
Study NCT02732093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Na.Cl 0.9% (placebo)
Study NCT02732093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2%
Study NCT02726061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based psychological support
Description: A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
Study NCT02942680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid started for 24 hours before surgery
Study NCT02942680 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: acetylsalicylic acid stayed for 5 days before surgery
Study NCT02778191 — intervention group
Intervention type: DRUG
Intervention: cisplatin
Description: 100 mg/m2 day 1, 22 and 43
Study NCT02778191 — intervention group
Intervention type: DRUG
Intervention: carboplatin
Description: carboplatin 300-350 mg/m2 day 1, 22 and 43
Study NCT02778191 — intervention group
Intervention type: DRUG
Intervention: 5-FU
Description: 5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
Study NCT02405117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiveWell System
Description: For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
Study NCT02746757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote conditioning
Study NCT02746757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Study NCT02129816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryophyllum
Study NCT02129816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bryophyllum
Study NCT02129816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryophyllum
Study NCT03408834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pulse variability index
Description: fluid management with pulse variability index or conventional
Study NCT03408834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulse variability index
Description: fluid management with pulse variability index or conventional
Study NCT04691713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeting CD276 autologous chimeric antigen receptor T cells
Description: Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
Study NCT04066985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset Online Single-Session Program
Description: 30minute self-administered program for youths
Study NCT02836964 — intervention group
Intervention type: DEVICE
Intervention: Crown placement
Description: Dental implant
Study NCT04066985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Kindness Online Single-Session Program
Description: 30minute self-administered program for youths
Study NCT04066985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy Online Single-Session Program (Control)
Description: 30minute self-administered active comparator program for youths
Study NCT01228344 — intervention group
Intervention type: OTHER
Intervention: Artemether-lumefantrine
Study NCT02762981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant with nab-paclitaxel
Description: Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.
Study NCT02106689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle free system
Description: Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
Study NCT02106689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard needle injection system
Description: Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
Study NCT04249336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-Calcium-Phospho-Silicate based dentifrices
Description: Bio-Active glass based formulation
Study NCT04249336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% Arginine based dentifrices
Description: Tubular occluding formulation
Study NCT04249336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% Strontium Acetate
Description: Tubular occluding formulation
Study NCT04249336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Fluoride
Description: No claim of relieving Dentin Hypersensitivity
Study NCT00937170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer LPS flex Gender Specific Implant (Total knee replacement)
Description: Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company